Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-01-20
2011-11-08
Tsang, Cecilia J (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S329000, C424S009300, C536S026600
Reexamination Certificate
active
08053415
ABSTRACT:
The present invention provides compounds that have motifs that target the compounds to cells that express integrins. In particular, the compounds have peptides with one or more RD motifs conjugated to an agent selected from an imaging agent and a targeting agent. The compounds may be used to detect, monitor and treat a variety of disorders mediated by integrins.
REFERENCES:
patent: 5972890 (1999-10-01), Lees et al.
patent: 6358920 (2002-03-01), Blaschuk et al.
patent: 6491894 (2002-12-01), Ruoslahti et al.
patent: 6610651 (2003-08-01), Ruoslahti et al.
patent: 2002/0041898 (2002-04-01), Unger et al.
patent: 2006078914 (2006-07-01), None
Bugaj 2001, Journal of Biomedical Optics, 6, 122-133.
International Search Report dated Aug. 2, 2007; 7 pages.
International Search Report regarding PCT/US06/02056, dated May 24, 2006; 5 pages.
Achilefu, S., Lighting up tumors with receptor-specific optical molecular probes, Technol. Cancer Res. Treat., 2004, pp. 393-409, vol. 3, No. 4.
Achilefu, S. et al, Novel receptor-targeted fluorescent contrast agents for in vivo tumor imaging, Invest Radiol, 2000, pp. 479-85, vol. 35, No. 8.
Achilefu, S, et al, Synthesis, in vitro receptor binding, and in vivo evaluation of fluorescein and carbocyanine peptide-based contrast agents, J. Med. Chem., 2002, pp. 2003-15, vol. 45m No. 10.
Achilefu, S, et al, Synergistic effects of light-emitting probes and peptides for targeting and monitoring intergrin expression, PNAS, 2005, pp. 7976-7981, vol. 102, No. 22.
Allman, R, et al, In vitro and in vivo effects of a cyclic peptide with affinity for the alpha(nu)beta3 integrin in human melanoma cells, Eur J Cancer, 2000, pp. 410-22. vol. 36, No. 3.
Arap, W, et al, Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model, Science, 1998, pp. 377-80, vol. 279, No. 5349.
Arnaout, Ma, Integrin structure: new twists and turns in dynamic cell adhesion, Immunol Rev, 2002, pp. 125-40, vol. 186.
Arnaout, Ma, et al, Coming to grips with integrin binding to ligands, Curr Opin Cell Biol, 2002, pp. 641-51, vol. 14, No. 5.
Bloch, et al, Targeting Beta-3 Integrin Using a Linear Hexapeptide Labeled with a Near-Infrared Fluorescent Molecular Probe, Molecular Pharmaceutics, 2006, pp. 539-549. vol. 3, No. 5.
Bloch, et al, Whole-body fluorescence lifetime imaging of a tumor-targeted near-infrared molecular probe in mice. J Biomed Opt., 2005, pp. 054003-1-054003-8, vol. 10, No. 5.
Bugaj, J, et al, Novel fluorescent contrast agents for optical imaging of in vivo tumors based on a receptor-targeted dye-peptide conjugate platform, J. Biomed Opt., 2001, pp. 122-33, vol. 6, No. 2.
Haubner, R, et al, Glycosylated RGD-Containing Peptides: Tracer for Tumor Targeting and Angiogenesis Imaging with Improved Biokinetics, The Journal of Nuclear Medicine, 2001, pp. 326-336, vol. 42, No. 2.
Haubner, R, et al, Radiolabeled ανβ3 Integrin Antagonists: A New Class of Tracers for Tumor Targeting, J Nucl Med, 1999, pp. 1061-1071, vol. 40.
Haubner, R, et al, Noninvasve Imaging of ανβ3 Integrin Expression Using 18F-labled RGD-containing Glycopeptide and Positron Emission Tomography, Cancer Research, 2001, pp. 1781-1785, vol. 61.
Janssen, M, et al, Tumor Targeting with Radiolabeled ανβ3 Integrin Binding Peptides in a Nude Mouse Model, Cancer Research, 2002, pp. 6146-6151, vol. 62.
Sivolapenko, GB, et al, Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide, Eur J Nucl Med, 1998, pp. 1383-1389, vol. 25, No. 10.
Van Hagen, PM, et al, Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy, Int J Cancer, 2000, pp. 186-198, vol. 90, No. 4.
Ye, Y, et al, Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors, J. Med. Chem., 2006, pp. 2268-2275. vol. 49, No. 7.
Ye, Y, et al, Polyvalent carbocyanine molecular beacons for molecular recognitions, J Am Chem, 2004, pp. 7740-7741, vol. 126, No. 25.
Ye Y, et al, Novel Near-Infrared Fluorescent Integrin-Targeted DFO Analogue, Bioconjugate Chem, 2008, pp. 225-234, vol. 19.
Ye, Y, et al, Multivalent carbocyanine molecular probes: synthesis and applications, Bioconjug Chem, 2005, pp. 51-61, vol. 16, No. 1.
Zhang, Z, et al, Monomolecular multimodal fluorescence-radioisotope imaging, Bioconjug Chem, 2005, pp. 1232-1239, vol. 16, No. 5.
Gudibande Satyanarayana
Polsinelli Shughart PC
Tsang Cecilia J
Washington University in St. Louis
LandOfFree
Compounds having RD targeting motifs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds having RD targeting motifs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds having RD targeting motifs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4294626